USP <800>: hazardous drug handling compliance stack

Layer 0 is the NIOSH HD List — the authoritative list of in-scope substances, updated periodically (current revision 2020, 2024 update in progress). Layer 1 is the Assessment of Risk (AoR) — for HDs other than antineoplastic dosage forms requiring manipulation, an entity may perform a documented AoR to determine alternative containment strategies; AoR cannot exclude antineoplastic dosage forms requiring any manipulation beyond counting/repackaging. Layer 2 is facility design — Containment Primary Engineering Controls (C-PEC) in a Containment Secondary Engineering Control (C-SEC) with externally-vented negative-pressure room, 30 air changes per hour minimum for sterile HD compounding, ISO Class 5 in the C-PEC, dedicated storage with negative pressure and 12 ACH minimum. Layer 3 is environmental and personnel controls — PPE (chemo-rated gloves double-gloved, gown, eye/face protection, respirator for spills), closed system transfer devices (CSTDs) required for administration and recommended for compounding of antineoplastics, surface wipe sampling, deactivation/decontamination/cleaning. Layer 4 is personnel — competency training, periodic reassessment, medical surveillance and exposure response.

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings classifies drugs in three tables: Table 1 antineoplastic (cytotoxic and non-cytotoxic anticancer), Table 2 non-antineoplastic meeting at least one NIOSH HD criterion, Table 3 drugs primarily with reproductive effects. USP <800> requires that all Table 1 antineoplastic active pharmaceutical ingredients and antineoplastic dosage forms requiring manipulation (anything beyond counting tablets or repackaging) be handled with full <800> containment. For Table 2 and 3, and for antineoplastic dosage forms not requiring manipulation, the entity may conduct an Assessment of Risk to define alternative containment strategies — the AoR documents drug type, dosage form, packaging, manipulation, exposure routes and risk-mitigation controls, and is reviewed at least every 12 months.

Sterile HD compounding requires a Containment Primary Engineering Control (C-PEC) — typically a Class II Type B2 BSC or a CACI — externally vented; located in a Containment Secondary Engineering Control (C-SEC) ISO Class 7 buffer room with negative pressure relative to adjacent area (0.01-0.03 inches water column), 30 air changes per hour minimum, externally vented; with an anteroom (positive pressure to corridor, negative or positive to buffer per chapter requirements) for hand hygiene and garbing. Non-sterile HD compounding requires a C-PEC (Containment Ventilated Enclosure or Class I BSC) in a non-classified C-SEC with negative pressure, 12 ACH minimum, externally vented. Storage of HDs requires a dedicated area with negative pressure to surroundings and 12 ACH minimum. Recirculation of HEPA-filtered air back to general HVAC is generally prohibited.

Personnel handling HDs must wear PPE per the chapter and the entity's risk assessment: chemo-rated gloves (ASTM D6978-rated) double-gloved when compounding, gown (ASTM-rated, single-use, fluid-resistant, back-closure), head/hair/shoe covers, eye and face protection where splash risk exists, NIOSH-approved respirator (N95 or higher; full-face for spills). Training and competency — initial training before handling, hands-on competency assessment, periodic reassessment (at least every 12 months). Medical surveillance program with baseline and periodic assessment for personnel routinely handling HDs (the OSHA-style program — not always implemented in practice but recommended in <800>). Exposure response procedure including spill kits, eye-wash availability and post-exposure protocol with documentation.

USP <800> recommends environmental wipe sampling for HD surface contamination at least every 6 months, with results trending to identify control gaps. No federal action level is specified; commonly-referenced limits include 1 ng/cm² for cyclophosphamide as a control benchmark. Deactivation/decontamination/cleaning (DDC) is a three-step process: deactivation with appropriate agent (commonly sodium hypochlorite followed by thiosulfate), decontamination to physically remove residual HD (water or appropriate solvent), cleaning with germicidal detergent. DDC sequence must be documented and validated; cleaning agents must be compatible with C-PEC manufacturer instructions.

USP <800> applies in addition to USP <795> for non-sterile HD compounding and USP <797> for sterile HD compounding. The 2023 revisions of <795> and <797> align with <800> facility requirements but each chapter retains distinct requirements (BUDs, environmental monitoring, garbing, training). OSHA HazCom (29 CFR 1910.1200) applies to all hazardous chemicals including HDs — SDS, labeling, HazCom plan and training are required. State Boards of Pharmacy enforce USP standards through pharmacy licensing and inspection; many states adopted <800> through state regulation independent of federal CMS deeming. CMS treats <800> as a Condition of Participation for Medicare-participating hospitals as of November 2023.

Conduct and maintain a current Assessment of Risk for non-antineoplastic HDs and antineoplastic dosage forms not requiring manipulation. Validate facility design against <800> with current room certifications (semi-annual for sterile, annual for non-sterile). Run the PPE programme with manufacturer testing data (ASTM D6978 chemo gloves, ASTM-rated gowns). Run competency training and document hands-on assessment. Establish wipe-sample programme with action levels and trending. Establish DDC SOP with cleaning-agent compatibility verification. Maintain spill response kits, eye-wash stations and post-exposure documentation. Track NIOSH HD List updates — additions trigger AoR and procedure updates.